NCT04128293View on ClinicalTrials.gov

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

November 15, 2019

Study Completion Date

November 15, 2019

Conditions
HIV Infections
Interventions
DRUG

GSK3640254 Tablet

GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

DRUG

GSK3640254 Capsule

GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT04128293 - A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants | Biotech Hunter | Biotech Hunter